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Introduction {#s1}
============

Cadmium (Cd) is a toxic heavy metal that is released into the environment from mining and industrial processes, the application of phosphate fertilizers, and fossil fuel combustion; it accumulates in soils and is readily taken up by plants ([@c3]). Human exposure primarily occurs via consumption of contaminated foods or through using tobacco products ([@c28]). Cadmium serves no biological role in humans and can cause severe health consequences such as kidney damage, bone and joint problems, and various cancers ([@c3]). Trace exposures to cadmium may also have toxic effects on pregnant mothers and on the developing fetus ([@c64]).

Recent epidemiologic studies have observed associations between Cd concentrations in maternal and/or fetal tissues with restricted fetal growth and pregnancy complications ([@c2], [@c1], [@c35], [@c32]; [@c36]; [@c42]; [@c70]). The toxic mechanisms that underlie these associations are not clear, although Cd is known to induce oxidative stress, interfere with cell-cycle regulation, alter apoptotic signaling at the cellular level ([@c65]), and to act as an endocrine disruptor ([@c30]). Additionally, the placenta provides a partial barrier against maternal--fetal Cd transfer, resulting in Cd accumulation in the placenta throughout pregnancy, although its accumulation within the placenta is likely not without consequence ([@c23]). Animal models and *in vitro* studies have suggested that maternal Cd exposure during pregnancy can perturb maternal--fetal nutrient and waste transfer ([@c33]; [@c71]), increase oxidative stress in placental tissue ([@c72]), interfere with placental glucocorticoid synthesis ([@c69]), and alter trophoblast proliferation and apoptosis ([@c16]). Thus, the placenta appears to be a critical target tissue for the toxic effects of Cd during human pregnancies.

We hypothesize that various Cd-associated perturbations to placental functions are likely linked to the selective expression or repression of specific biological pathways. Similarly, maternal Cd exposure during pregnancy has been associated with variations in DNA methylation (DNAM), an epigenetic mechanism that regulates gene expression potential, in maternal and fetal blood samples ([@c67]). To date, only one study has investigated associations between placental Cd and DNAM throughout the placental genome in humans. Mohanty et al ([@c44]) explored Cd-associated DNAM in a small study of 24 placentae, identifying multiple differentially methylated loci nearby or within genes involved in cell damage, angiogenesis, cell differentiation, and organ development; these associations differed by fetal sex ([@c44]). Studies with larger samples using recent methodological advances to estimate and adjust for tissue heterogeneity are needed to understand how Cd exposure influences the placental epigenome of human pregnancies and whether such variations are related to fetal growth restriction.

We conducted a study of the associations between placental Cd and placental DNAM throughout the epigenome across two well-characterized independent cohorts while examining the potential impact of tissue heterogeneity on these associations. Secondarily, we investigated whether the top hits from our analysis were enriched for biological pathways consistent with findings from other studies; whether differentially methylated loci were associated with the expression levels of nearby genes; and whether these variations in expression were associated with standardized measures of birth weight, birth length, and head circumference.

Methods {#s2}
=======

New Hampshire Birth Cohort Study {#s2.1}
--------------------------------

This study included mother--infant pairs from the New Hampshire Birth Cohort Study (NHBCS), an ongoing birth cohort initiated in 2009. Women who were currently pregnant, were between 18 and 45 y of age, were receiving prenatal care from one of the study clinics in New Hampshire, who reported that the primary source of drinking water at their residence was from an unregulated well, and who had resided in the same household since their previous menstrual period with no plans to move before delivery were enrolled in the cohort. All participants provided written informed consent in accordance with the requirements of the Institutional Review Board (IRB) of Dartmouth College. The sample for this study consisted of NHBCS participants who were recruited between February 2012 and September 2013, whose placenta were sampled to conduct genetic and epigenetic assays ($n = 343$). Placental gross measures such as placental diameter (cm) and placental weight (g) were collected immediately after delivery. Interviewer-administered questionnaires and medical record abstraction were utilized to collect sociodemographic, lifestyle, and anthropometric data.

Rhode Island Child Health Study {#s2.2}
-------------------------------

The Rhode Island Child Health Study (RICHS) enrolled mother--infant pairs with nonpathologic pregnancies at the Women & Infants Hospital in Providence, Rhode Island, between September 2010 and February 2013. Exclusion criteria consisted of mothers being $< 18\; y$ of age or having life-threatening conditions, pregnancies with gestational time $< 37\;{wk}$, or infants with congenital/chromosomal abnormalities. All protocols were approved by the institutional review boards at the Women & Infants Hospital of Rhode Island and Dartmouth College, and all participants provided written informed consent. Infants who were born small for gestational age \[$\leq 10\text{th}$ birth weight (BW) percentile\] or large for gestational age ($\geq 90\text{th}$ BW percentile) were oversampled; then, infants who were adequate for gestational age (between the 10th and 90th BW percentiles) that matched on gestational age and maternal age were coincidentally enrolled. This study included all mother--infant pairs for whom placental metal concentrations and placental DNAM arrays had been conducted ($n = 141$). Interviewer-administered questionnaires were utilized to collect sociodemographic and lifestyle data; anthropometric and medical history data were obtained via structured medical records review. Samples with complete covariate, exposure, and outcome data were utilized for this study.

Anthropometric Measures {#s2.3}
-----------------------

Birth weight (g), head circumference (cm), and birth length (cm) were abstracted from medical records. *z*-Scores were calculated for each, standardized by gestational time and infant sex, via Fenton growth curves ([@c20]). We classified infants with standardized BW percentiles below the 10th percentile as small for gestational age (SGA), those above the 90th percentile as large for gestational age (LGA), and those between the 10th and 90th percentile as adequate for gestational age (AGA).

Potential Covariates {#s2.4}
--------------------

Highest achieved maternal education level was self-reported and was defined as those with education beyond the high school level versus those who did not go beyond high school. Maternal smoking during pregnancy was defined as any self-reported smoking during any point of pregnancy versus those who reported no smoking during pregnancy. Fetal sex was abstracted from medical records. Samples with complete covariate, placental Cd, and placental DNAM data were utilized for this study.

Sample Collection {#s2.5}
-----------------

Placenta samples from RICHS and NHBCS were biopsied from the fetal side adjacent to the cord insertion site within 2 h of delivery, and maternal decidua was removed. Samples were placed in RNAlater (Life Technologies) and then frozen at $- 80{^\circ}C$. Both RNA and DNA were extracted (Norgen Biotek) and quantified using a Qubit Flourometer (Life Technologies) and were subsequently stored at $- 80{^\circ}C$. Both cohorts followed the same sampling protocol.

DNA Methylation, Quality Control, and Normalization {#s2.6}
---------------------------------------------------

Both cohorts measured DNAM via Illumina Infinium HumanMethylation450K BeadArray (Illumina) at the University of Minnesota Genomics Center. Bisulfite modification was performed with an EZ Methylation kit (Zymo Research, Irvine, CA), samples were randomized across multiple batches, batch variables were recorded to allow for batch-effect corrections, and data were assembled using BeadStudio (Illumina). The raw array data are available via the NCBI Gene Expression Omnibus (GEO) for NHBCS and RICHS via accession numbers GSE71678 and GSE75248, respectively. For quality control (QC), we excluded probes with poor detection *p*-values ($p\text{-value} > 0.001$), measuring DNAM at X- and Y-linked CpG sites, with a single nucleotide polymorphism (SNP) within 10 bp of the target CpG or single base extension (SBE) (and allelic frequency $> 1\%$), or cross-hybridizing to multiple genomic regions ([@c11]). Background correction, dye bias, and functional normalization were performed via the minfi package ([@c21]), and standardization across probe types was performed via beta mixture quantile (BMIQ) normalization ([@c62]). Batch effects were corrected for using empirical Bayes via the combat function in R ([@c31]). We examined whether principal components from the methylation array were associated with batch variables and found no indications of remaining batch effects after this correction. We also confirmed that batch variables were not associated with continuous \[analysis of variance (ANOVA) *p*-values: $\text{NHBCS} = 0.326$, $\text{RICHS} = 0.762$\] or dichotomous Cd ($\chi^{2}$ *p*-values: $\text{NHBCS} = 0.980$, $\text{RICHS} = 0.688$) in either cohort. DNAM data were reported as $\beta\text{-values}$, representing the proportion of methylated alleles for each individual CpG site. For the epigenome-wide association (EWAS) models described below we utilized *M*-values, logit-transformation of the beta values, which better approximate a normal distribution ([@c14]).

RNA Sequencing, QC, and Normalization {#s2.7}
-------------------------------------

Transcriptome-wide sequencing was performed on 200 placental samples from RICHS. We used an RNeasy Mini Kit (Qiagen) to isolate total RNA, which was then stored at $- 80{^\circ}C$ until analysis. We quantified RNA using a Nanodrop Spectrophoto-meter (Thermo Scientific), assessed RNA integrity via Agilent Bioanalyzer (Agilent), removed ribosomal RNA with a Ribo-Zero Kit ([@c26]), converted to cDNA using random hexamers (Thermo Scientific), and performed transcriptome-wide RNA sequencing via the HiSeq 2500 platform (Illumina) ([@c7]). Raw reads have been deposited at the NCBI sequence read archive (SRP095910). QC was performed in FastQC; then, reads were mapped to the human reference genome (h19) using the Spliced Transcripts Alignment to a Reference (STAR) aligner. Low-expressed genes were excluded, and read counts were adjusted for GC content ([@c50]) and then normalized via the trimmed mean of *M*-values (TMM) ([@c51]); final data are normalized $\log_{2}$ counts per million (logCPM) reads.

Cadmium Quantification {#s2.8}
----------------------

Trace element concentrations were quantified in RICHS and NHBCS placental samples at the Dartmouth Trace Elements Analysis Core using inductively coupled plasma mass spectrometry (ICP-MS); details of the processing are described elsewhere ([@c49]). None of the RICHS samples had nondetectable Cd concentrations, and only four of the NHBCS samples received nondetects, which were assigned a value equal to the 0.5th percentile of detectable values. Owing to the skewed nature of the Cd concentration distributions and to the infeasibility of exploring modeling assumptions for all EWAS models, we dichotomized cadmium concentrations by the cohort-specific median concentrations (NHBCS $\text{median} = 3.13\,\text{ng}/g$) and (RICHS $\text{median} = 4.37\,\text{ng}/g$) for the EWAS analysis. Cd concentrations were $\log_{2}$-transformed for follow-up analyses of significant findings, which utilized continuous data.

Estimation of Placental Tissue Heterogeneity {#s2.9}
--------------------------------------------

We addressed the potential issue of confounding due to DNAM-associated tissue heterogeneity via the RefFreeEWAS package in R ([@c25]). This method utilized nonnegative matrix factorization to estimate the proportions of putative cellular mixtures and has been demonstrated to yield reliable estimates of the constituent cell types and the underlying methylomes that define them ([@c25]). Using the 10,000 CpGs with the greatest variability in DNAM, we identified four and five putative constituent cell mixtures in the RICHS and NHBCS cohorts, respectively, and then used the full set of CpGs for each cohort (NHBCS $p = 408,367$ and RICHS $p = 397,040$) to estimate the relative proportions of each putative cell type per placental sample. We examined whether the 10,000 CpGs with the largest variance across putative cell-type-specific DNAM values were enriched for gene ontology (GO) terms or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways via the gometh function in the missMethyl package in R ([@c48]). This method adjusts for the potential bias introduced by some genes having a greater probability of being included in the gene set because they have greater numbers of CpGs on the 450K array. We examined the consistency of the CpGs with high cell-type-specific DNAM as well as the consistency in the top 100 GO terms and KEGG pathways associated with those highly variable CpGs.

Epigenome-Wide Association Study {#s2.10}
--------------------------------

Robust linear regressions (rlm) were used to estimate the associations between CpG-specific DNAM levels and high versus low placental concentrations of Cd. We produced two covariate-adjusted models for each CpG within each cohort, first regressing *M*-values on dichotomized Cd concentrations (cohort-specific median as the reference) while adjusting for infant sex, maternal smoking during pregnancy, and highest achieved maternal education level. Second, we produced the same models while also adjusting for the estimated proportions of putative placental cell types. Genomic inflation was examined via the genomic inflation factor ($\lambda$), which was calculated using the genABEL package in R ([@c4]). We selected the 250 CpGs with the smallest Cd-associated meta-analysis *p*-values and assessed these for functional enrichment with GO terms and KEGG pathways as described above. Statistical significance for enrichment was determined at a 5% false discovery rate (FDR).

Meta-Analyses {#s2.11}
-------------

We used METAL to meta-analyze the cohort-specific Cd-associations via inverse variance weighted fixed effects models, and we evaluated interstudy heterogeneity via Cochran\'s Q-test $p\text{-values} < 0.05$. ([@c73]). We produced FDR-adjusted *p*-values using the qvalue package in R. Statistical significance was determined at an FDR of 5%. Volcano plots were produced to visualize the overall magnitude and direction of associations, and Manhattan plots were produced using the qqman package to visualize the genomic distribution of significant associations. Plots for specific regions of the genome were visualized using the coMET package ([@c40]). Top hits from the study were also evaluated for dose--response relationships via modeling associations between $\log_{2}$-transformed continuous Cd and DNAM, using linear mixed models, allowing for random intercepts by study. Plots of FDR-significant hits utilized DNAM $\beta\text{-values}$ as the dependent variable for more intuitive interpretation.

Expression Quantitative Trait Methylation Analysis {#s2.12}
--------------------------------------------------

We then tested whether any of the Cd-associated CpGs ($p\text{-values} < 1 \times 10^{- 5}$) could be expression quantitative trait methylation (eQTM) loci within the 200 RICHS samples, 85 of which overlap with the samples used in the EWAS. We tested for *cis*-gene--CpG associations (within $100\,\text{kb}$ of the target CpG site) by regressing gene expression levels ($\log_{2}\left( \text{CPM} \right)$) on CpG $\beta\text{-values}$ using robust linear models. Statistical significance for eQTM associations was determined at a 5% FDR.

Associations with Fetal Growth {#s2.13}
------------------------------

Genes that were identified as potential eQTMs at a 5% FDR threshold were then tested for associations between birth metrics and gene expression using Kendal correlations, a nonparametric correlation test that allows for ties. Because birth metric *z*-scores were standardized by fetal sex and by weeks of gestation, no additional adjustments were made to these association tests.

Replication of Previous Studies and Sex-Specific Effects {#s2.14}
--------------------------------------------------------

We then investigated whether we could reproduce the results from a previous study of sex-specific associations between placental Cd and placental DNAM ([@c44]). Because multiple studies of various fetal and maternal tissues have suggested that associations between Cd and DNAM may differ by fetal sex ([@c32]; [@c44]; [@c68]), we also screened the CpGs from our study with meta-analysis $p\text{-values} < 1 \times 10^{- 5}$ for interactions with fetal sex. For these analyses, we utilized linear mixed models with DNAM *M*-values as the outcome, allowing for random intercepts by study, and we included an interaction term between DNAM levels and fetal sex while adjusting for maternal education and maternal smoking. We utilized the Wald test to produce *p*-values and determined statistically significant interactions at a *p*-value threshold of 0.05. Any models producing interaction $p\text{-values} < 0.05$ were then rerun stratified by fetal sex.

Results {#s3}
=======

The EWAS for this study included 343 mother--infant pairs drawn from the New Hampshire Birth Cohort (NHBCS) and 141 mother--infant pairs from the Rhode Island Child Health Study (RICHS). The most notable differences between the NHBCS and RICHS samples ([Table 1](#t1){ref-type="table"}) were with regard to racial diversity and birth size. Because RICHS was over-sampled for LGA and SGA infants by design, we observed a higher proportion of SGA and LGA infants compared with NHBCS. Placental samples from the RICHS cohort also had slightly higher median Cd concentrations ($4.34\,\text{ng}/g$) than samples from the NHBCS cohort ($3.13\,\text{ng}/g$), and concentrations were approximately log-normally distributed in both cohorts (see Figure S1).

###### 

Maternal and offspring characteristics for the NHBCS ($n = 343$) and RICHS ($n = 141$) samples.

Table 1 lists maternal and offspring characteristics in the first column; the corresponding values for NHBCS and RICHS are listed in the other columns.

  Maternal characteristics                                       NHBCS[^*a*^](#t1n1){ref-type="table-fn"}   RICHS[^*a*^](#t1n1){ref-type="table-fn"}
  -------------------------------------------------------------- ------------------------------------------ ------------------------------------------
  Smoking during pregnancy                                                                                   
   Any                                                           21 (6.1%)                                  19 (13.5%)
   None                                                          322 (93.9%)                                122 (86.5%)
  Educational attainment                                                                                     
   High school or less                                           37 (10.8%)                                 34 (24.1%)
   More than high school                                         306 (89.2%)                                107 (75.9%)
  Ethnicity                                                                                                  
   Not white                                                     6 (1.7%)                                   36 (25.5%)
   White                                                         337 (98.3%)                                105 (74.5%)
  Infant characteristics                                                                                    
   Gestational age (weeks)                                       38.95 (1.54)                               39.33 (1.00)
   Birth weight (g)[^*b*^](#t1n2){ref-type="table-fn"}           3435.14 (510.95)                           3623.09 (716.03)
   Size for gestational age[^*b*^](#t1n2){ref-type="table-fn"}                                               
    SGA                                                          15 (4.4%)                                  21 (14.9%)
    AGA                                                          292 (86.1%)                                68 (48.2%)
    LGA                                                          32 (9.4%)                                  52 (36.9%)
   Sex                                                                                                       
    Female                                                       159 (46.4%)                                68 (48.2%)
    Male                                                         184 (53.6%)                                73 (51.8%)
  Placental Cd (ng/g)[^*c*^](#t1n3){ref-type="table-fn"}                                                    
  Overall                                                        3.13 (2.61)                                4.37 (2.71)
  Below cohort-specific median                                   2.07 (1.05)                                2.78 (1.35)
  Above cohort-specific median                                   4.68 (2.32)                                5.49 (2.44)

Note: AGA, adequate for gestational age; Cd, cadmium; LGA, large for gestational age; NHBCS, New Hampshire Birth Cohort Study; RICHS, Rhode Island Child Health Study; SGA, small for gestational age.

Means and standard deviations are presented for continuous variables, whereas frequencies and percentages are presented for categorical variables.

Four samples were missing for birth weight and SGA/AGA/LGA classifications in the NHBCS; all other continuous and categorical variables had no missing values.

Medians and interquartile ranges (IQRs) presented owing to skewed distributions of Cd concentrations.

We regressed DNAM *M*-values (at 408,367 CpGs in NHBCS and 397,040 CpGs in RICHS) on dichotomized placental Cd concentrations (median split) while adjusting for fetal sex, maternal smoking during pregnancy, and maternal education level in each cohort. We then combined parameter estimates and *p*-values via inverse variance weighted fixed effects meta-analysis (390,583 CpGs overlapped between the cohorts), which yielded three loci with Cd associations at a 5% FDR and 18 additional loci with $p\text{-values} < 1 \times 10^{- 5}$ ([Table 2](#t2){ref-type="table"}), in which Cd was predominantly associated with hypermethylation.

###### 

Results from cohort-specific and meta-analyses of Cd-associated DNA methylation, for probes with meta-analysis $p\text{-values} < 1 \times 10^{- 5}$; adjusted for maternal smoking during pregnancy, maternal education, and fetal sex.

Table 2 lists CpG ID, chromosome, genomic position, gene, regulatory feature in the first, second, third, forth, and fifth columns, respectively. The values of beta sub 1, p-values, and FDR for the meta-analysis; beta sub 1 and p-values for NHBCS (n equals 343); and beta sub 1 and p-values for RICHS (n equals 141) are listed in the other columns.

  CpG annotations   Meta-analysis   NHBCS ($n = 343$)   RICHS ($n = 141$)                                                                                                        
  ----------------- --------------- ------------------- ------------------- -------------- --------- ----------------------- ------- --------- ----------------------- --------- -----------------------
  cg16034168        1               6336711             *ACOT7*             Body                0.39 $1.92 \times 10^{-6}$   0.107        0.48 $4.47 \times 10^{-5}$        0.31 $7.39 \times 10^{-3}$
  cg18384460        1               63771428            *-*                 \-                  0.35 $2.22 \times 10^{-6}$   0.107        0.43 $1.44 \times 10^{-5}$        0.25 $2.42 \times 10^{-2}$
  cg08705382        1               230322024           *GALNT2*            Body                0.34 $9.51 \times 10^{-6}$   0.151        0.34 $8.06 \times 10^{-4}$        0.35 $3.79 \times 10^{-3}$
  cg26262055        4               25090618            *-*                 \-                  0.22 $8.94 \times 10^{-6}$   0.151        0.29 $1.15 \times 10^{-2}$        0.21 $2.12 \times 10^{-4}$
  cg26653990        5               72510846            *-*                 \-                  0.23 $8.75 \times 10^{-6}$   0.151        0.25 $1.41 \times 10^{-4}$        0.19 $1.87 \times 10^{-2}$
  cg00766220        5               72598865            *-*                 \-                  0.14 $4.37 \times 10^{-6}$   0.147        0.13 $3.32 \times 10^{-4}$        0.14 $4.13 \times 10^{-3}$
  cg09391066        6               3163814             *-*                 \-                  0.19 $6.10 \times 10^{-6}$   0.151        0.21 $1.10 \times 10^{-3}$        0.18 $1.65 \times 10^{-3}$
  cg03797906        7               28994696            *TRIL*              3′UTR; Body         0.17 $9.62 \times 10^{-6}$   0.151        0.21 $2.48 \times 10^{-4}$        0.14 $7.97 \times 10^{-3}$
  cg11157440        8               19316005            *CSGALNACT1*        Body                0.29 $7.64 \times 10^{-6}$   0.151        0.28 $6.19 \times 10^{-4}$        0.30 $3.91 \times 10^{-3}$
  cg21437157        8               27346608            *-*                 \-                  0.23 $4.12 \times 10^{-6}$   0.147        0.19 $1.53 \times 10^{-3}$        0.33 $3.32 \times 10^{-4}$
  cg05888894        8               119107030           *EXT1*              Body                0.33 $2.81 \times 10^{-7}$   0.046        0.33 $5.56 \times 10^{-3}$        0.33 $1.54 \times 10^{-5}$
  cg03509329        14              24520788            *LRRC16B*           TSS1500             0.15 $7.09 \times 10^{-6}$   0.151        0.19 $9.15 \times 10^{-4}$        0.12 $1.47 \times 10^{-3}$
  cg15345741        14              103674333           *-*                 \-                  0.28 $4.10 \times 10^{-7}$   0.046        0.28 $2.52 \times 10^{-4}$        0.29 $4.64 \times 10^{-4}$
  cg17232357        15              67012832            *SMAD6*             Body             $-0.19$ $2.16 \times 10^{-6}$   0.107     $-0.17$ $1.04 \times 10^{-2}$     $-0.21$ $5.85 \times 10^{-5}$
  cg12642651        17              9861712             *GAS7*              Body                0.38 $5.81 \times 10^{-6}$   0.151        0.27 $2.78 \times 10^{-2}$        0.48 $3.09 \times 10^{-5}$
  cg03762242        17              9940004             *GAS7*              Body; 5′UTR         0.26 $3.38 \times 10^{-6}$   0.142        0.26 $7.76 \times 10^{-4}$        0.26 $1.34 \times 10^{-3}$
  cg16768966        17              9940227             *GAS7*              Body; TSS200        0.37 $4.05 \times 10^{-7}$   0.046        0.34 $1.55 \times 10^{-3}$        0.40 $6.93 \times 10^{-5}$
  cg15285733        17              10039537            *GAS7*              Body                0.17 $7.32 \times 10^{-7}$   0.062        0.16 $2.42 \times 10^{-3}$        0.18 $8.78 \times 10^{-5}$
  cg02393525        17              40687925            *NAGLU*             TSS200              0.23 $8.90 \times 10^{-6}$   0.151        0.16 $3.33 \times 10^{-2}$        0.31 $3.13 \times 10^{-5}$
  cg06707369        19              36400425            *TYROBP*            TSS1500             0.17 $7.49 \times 10^{-6}$   0.151        0.19 $2.35 \times 10^{-4}$        0.15 $8.89 \times 10^{-3}$
  cg11707084        19              48345263            *CRX*               3′UTR               0.23 $7.79 \times 10^{-6}$   0.151        0.25 $1.37 \times 10^{-4}$        0.19 $1.68 \times 10^{-2}$

Note: Ch., chromosome; CpG, cytosine-phosphate-guanine methylation site; FDR, false discovery rate adjusted *p*-value; NHBCS, New Hampshire Birth Cohort; RICHS, Rhode Island Child Health Study; TSS200, within 200 bp of the transcription start site; TSS1500, within 1,500 bp of the transcription start site; UTR, untranslated region.

Cell-specific DNAM is a well-recognized confounder in epigenetic epidemiology, leading many studies to estimate the proportions of constituent cell types from the DNAM array data ([@c24]) and to adjust for these proportions in their regression models. However, estimation of cell-type proportions requires access to cell-type-specific methylomes for the individual cells that constitute the heterogenous tissue under study, and no reference methylomes currently exist for placental tissue. Thus, we used a reference-free method that deconvoluted the major axes of variation in DNAM, which are likely associated with tissue heterogeneity, to estimate the proportions of the putative constituent cell types (PCTs) in our placental samples ([@c25]). With this method, we estimated five and four PCTs in NHBCS and RICHS, respectively. We then tested whether the 10,000 CpGs with the greatest variability in PCT-specific DNAM were enriched for biologically relevant GO terms or KEGG pathways, and we checked for consistency between the two cohorts. We observed 31.6% overlap among these 10,000 PCT-defining CpGs and strong concordance in the biological functions of the top 100 GO terms (60% overlap) and KEGG pathways (76% overlap) across the two cohorts. The top 10 KEGG pathways from both cohorts included metabolic pathways, neuroactive ligand--receptor interaction, axon guidance, calcium signaling, olfactory transduction, cell adhesion molecules (CAMs), and cAMP signaling (see Excel Tables S1 and S2; see also Figure S2).

We then tested whether the distribution of these PCTs varied with placental Cd concentrations. Higher Cd was associated with increased proportions of PCT-1 (3.4% difference, T-test $p\text{-value} = 0.010$) and PCT-2 (4.7% difference, T-test $p\text{-value} = 0.022$) in NHBCS, whereas higher Cd was associated with increased proportions of PCT-2 (7.3% difference, T-test $p\text{-value} = 0.047$) in RICHS. Because these associations may confound the relationships between Cd and locus-specific DNAM, we then reproduced the cohort-specific multivariable models and meta-analysis while also adjusting for the estimated PCT pro-portions. These adjustments substantially reduced inflation in NHBCS ($\lambda = 1.47$ before adjustment and $\lambda = 0.96$ after adjustment), and only modestly increased inflation in RICHS ($\lambda = 1.03$ before adjustment and $\lambda = 1.10$ after adjustment). Furthermore, the PCT adjustments reduced the proportion of small heterogeneity *p*-values ($< 0.05$) in the meta-analysis from 7.9% in the non-PCT-adjusted models to 4.6% in the PCT-adjusted models. (See Excel Table S3 and Excel Table S4 for full results from all cohort-specific and meta-analyses).

We compared the meta-analysis parameter estimates and *p*-values before and after PCT adjustment across all CpGs via plots, LOESS curves, and Spearman correlations. We found that overall, the parameter estimates tended to become attenuated by PCT adjustment (see Figure S3) and produced fewer small *p*-values (see Figure S4), indicating an overall confounding by estimated cellular heterogeneity. For example, the parameter estimates for our top three hits from the original meta-analysis (cg15345741, cg16768966, and cg05888894) were reduced by 11%, 16%, and 45%, respectively, after adjustment for PCTs, indicating that cell mixture likely explained much of the Cd-associated variation for cg05888894, but only a modest proportion of the Cd-DNAM associations at cg15345741 and cg16768966. Additionally, the coefficients for cg15345741 and cg16768966 retained highly significant *p*-values ($< 1 \times 10^{- 5}$) after PCT adjustment. Despite a tendency towards attenuation, the estimated effects before and after adjustment were highly correlated ($\rho = 0.81$, $p\text{-value} = \text{less}\,\text{than}\, 2.2 \times 10^{- 16}$), although *p*-values were only moderately correlated ($\rho = 0.60$, $p\text{-value} < 2.2 \times 10^{- 16}$). Overall, higher Cd was more commonly associated with higher DNAM, and our suggestive and FDR-significant hits were spread throughout the genome ([Figure 1](#f1){ref-type="fig"}).

![Volcano plots from each cohort-specific epigenome-wide association study (EWAS) and the meta-analysis, and Manhattan plot of meta-analysis results. All models adjusted for fetal sex, maternal smoking during pregnancy, mother's highest achieved education level, and putative placental cell types; dashed line represents the false discovery rate (FDR) 5% threshold; dotted line represents suggestive association ($p\text{-values} < 1 \times 10^{- 5}$).](EHP2192_f1){#f1}

The PCT-adjusted top hit from NHBCS was cg20656525 on chromosome 14, downstream of the genes encoding TNF alpha induced protein 2 (*TNFAIP2*) and exocyst complex component 3 like 4 (*EXOC3L4*), whereas the top hit from RICHS was cg07708653 on chromosome 1, within the body of the 4-hydroxyphenylpyruvate dioxygenase like (*HPDL*) gene. The PCT-adjusted meta-analysis yielded 17 CpGs with Cd-association $p\text{-values} < 1 \times 10^{- 5}$ ([Table 3](#t3){ref-type="table"}), two of which were significant at a 5% FDR (cg15345741 and cg11707084). Both of the FDR-significant CpGs also had significant linear associations with log-Cd (cg15345741 $\text{estimate} = 0.17$, $p\text{-value} = 0.00019$; cg11707084 $\text{estimate} = 0.16$, $p\text{-value} = 0.000014$) in linear mixed models. For these two CpGs, we regressed DNAM $\beta\text{-values}$ over dichotomized Cd, continuous Cd, and log-transformed Cd, using the pooled data adjusted for the same covariates and an indicator for study to visualize the approximate percent change in DNAM associated with Cd ([Figure 2](#f2){ref-type="fig"}). The meta-analyses again revealed a clear trend towards higher DNAM levels associated with higher Cd concentrations; 94% of Cd-associated loci with $p\text{-values} < 1 \times 10^{- 5}$ had positive beta coefficients. Of note, 41% of CpGs with suggestive *p*-values ($< 1 \times 10^{- 5}$) were on chromosome 17, five of which were within the growth arrest specific 7 (*GAS7*) gene. Given the high proportion of *GAS7* CpGs among the top hits from the meta-analysis, we explored the comethylation structure within *GAS7* and all Cd-DNAM associations within and around this gene. The strongest Cd-associated DNAM sites tended to congregate around the first exons of three of the four different *GAS7* variants (*GAS7*-a, -b, and -d) and exhibited a strong comethylation structure as shown by strong positive Spearman correlation *p*-values ([Figure 3](#f3){ref-type="fig"}).

![Differences in average DMA methylation (DNAM) by cadmium (Cd) as a dichotomous, continuous, and log-transformed variable (panels *A*, *B*, and *C*, respectively), at the two false discovery rate (FDR)-significant CpGs (left, cg11701084; right, cg15345741). Robust linear regression models were adjusted for fetal sex, maternal smoking during pregnancy, mother's highest achieved education level, putative placental cell types, and an indicator for study \[New Hampshire Birth Cohort Study (NHBCS) and Rhode Island Child Health Study (RICHS)\]. For models of dichotomous Cd, values were classified as low or high according to the median value for each cohort (3.13 and $4.37\,\text{ng}/g$ for NHBCS and RICHS, respectively.).](EHP2192_f2){#f2}

![Manhattan plot of Cd meta-analysis results surrounding the GAS7 gene. Annotated with Ensembl gene names and RefSeq IDs for GAS7 variants, Spearman correlations between GAS7 CpG sites, and CpG-expression correlations. Cadmium (Cd) associations at CpGs outside of the GAS7 coding region ($\pm 1,500\,\text{bp}$) have triangles, whereas CpGs within GAS7 have squares; hits with meta-analysis $p\text{-values} < 1 \times 10^{- 5}$ are indicated with an asterisk (\*). Directions of association between DNA methylation (DNAM) and GAS7 expression are indicated with $+$ and $-$ signs for those relationships whose Spearman correlation *p*-values were nominally significant ($p\text{-values} < 0.05$).](EHP2192_f3){#f3}

###### 

Results from cohort-specific and meta-analyses of cadmium-associated DNA methylation, for probes with meta-analysis $p\text{-values} < 1 \times 10^{- 5}$; adjusted for maternal smoking during pregnancy, maternal education, fetal sex, and estimated tissue heterogeneity.

Table 3 lists CpG ID, chromosome, genomic position, gene, regulatory feature in the first, second, third, forth, and fifth columns, respectively. The values of beta sub 1, p-values, and FDR for the meta-analysis; beta sub 1 and p-values for NHBCS (n equals 343); and beta sub 1 and p-values for RICHS (n equals 141) are listed in the other columns.

  CpG annotations                                 Meta-analysis   NHBCS ($n = 343$)   RICHS ($n = 141$)                                                                                                         
  ----------------------------------------------- --------------- ------------------- ------------------- --------------- --------- ----------------------- ------- --------- ----------------------- --------- -----------------------
  cg16034168[^*a*^](#t3n1){ref-type="table-fn"}   1               6336711             *ACOT7*             Body                 0.32 $2.80 \times 10^{-6}$   0.171        0.32 $3.11 \times 10^{-4}$        0.32 $2.78 \times 10^{-3}$
  cg24000528                                      2               177013630           *MIR10B*            TSS1500              0.16 $7.59 \times 10^{-6}$   0.182        0.18 $1.52 \times 10^{-3}$        0.16 $1.50 \times 10^{-3}$
  cg24696183                                      11              2891360             *KCNQ1DN*           Body              $-0.16$ $4.31 \times 10^{-6}$   0.171     $-0.20$ $5.67 \times 10^{-4}$     $-0.14$ $1.71 \times 10^{-3}$
  cg23193177                                      11              45717613            *-*                 \-                   0.24 $4.68 \times 10^{-6}$   0.171        0.22 $4.94 \times 10^{-4}$        0.27 $2.70 \times 10^{-3}$
  cg15345741[^*a*^](#t3n1){ref-type="table-fn"}   14              103674333           *-*                 \-                   0.25 $1.49 \times 10^{-7}$   0.04         0.25 $9.69 \times 10^{-5}$        0.24 $4.22 \times 10^{-4}$
  cg06100161                                      15              60987894            *RORA*              Body                 0.20 $1.97 \times 10^{-6}$   0.171        0.12 $6.28 \times 10^{-2}$        0.28 $1.99 \times 10^{-6}$
  cg03917020                                      16              85285139            *-*                 \-                   0.14 $5.52 \times 10^{-6}$   0.174        0.13 $3.62 \times 10^{-4}$        0.14 $4.85 \times 10^{-3}$
  cg02600679                                      16              88832700            *PIEZO1*            Body                 0.25 $4.92 \times 10^{-6}$   0.171        0.17 $2.55 \times 10^{-2}$        0.34 $2.02 \times 10^{-5}$
  cg04267691                                      17              9862752             *GAS7*              Body; 5\'UTR         0.18 $6.98 \times 10^{-6}$   0.178        0.12 $3.09 \times 10^{-2}$        0.24 $2.57 \times 10^{-5}$
  cg10517535                                      17              9929698             *GAS7*              Body; TSS200         0.31 $6.46 \times 10^{-6}$   0.177        0.16 $6.97 \times 10^{-2}$        0.59 $3.08 \times 10^{-7}$
  cg03762242[^*a*^](#t3n1){ref-type="table-fn"}   17              9940004             *GAS7*              Body; 5\'UTR         0.23 $3.33 \times 10^{-6}$   0.171        0.20 $2.08 \times 10^{-3}$        0.26 $4.12 \times 10^{-4}$
  cg16768966[^*a*^](#t3n1){ref-type="table-fn"}   17              9940227             *GAS7*              Body; TSS200         0.31 $1.92 \times 10^{-6}$   0.171        0.23 $7.31 \times 10^{-3}$        0.42 $3.12 \times 10^{-5}$
  cg10618704                                      17              9940970             *GAS7*              TSS1500; Body        0.36 $5.91 \times 10^{-6}$   0.174        0.24 $2.03 \times 10^{-2}$        0.54 $1.65 \times 10^{-5}$
  cg11851174                                      17              17712609            *RAI1*              Body                 0.19 $3.69 \times 10^{-6}$   0.171        0.20 $1.07 \times 10^{-4}$        0.18 $1.10 \times 10^{-2}$
  cg19944656                                      17              76876040            *TIMP2*             Body                 0.18 $2.62 \times 10^{-6}$   0.171        0.17 $8.06 \times 10^{-5}$        0.18 $9.82 \times 10^{-4}$
  cg11707084[^*a*^](#t3n1){ref-type="table-fn"}   19              48345263            *CRX*               3\'UTR               0.22 $2.09 \times 10^{-7}$   0.04         0.23 $3.10 \times 10^{-5}$        0.22 $1.93 \times 10^{-3}$
  cg03566291                                      21              44831040            *-*                 \-                   0.23 $9.46 \times 10^{-6}$   0.201        0.21 $9.57 \times 10^{-4}$        0.29 $2.38 \times 10^{-3}$

Note: Ch., chromosome; CpG, cytosine-phosphate-guanine methylation site; FDR, false discovery rate adjusted *p*-value; NHBCS, New Hampshire Birth Cohort; RICHS, Rhode Island Child Health Study; TSS200, within 200 bp of the transcriptions start site; TSS1500, within 1500 bp of the transcription start site; UTR, untranslated region.

CpG Sites that yielded meta-analysis $p\text{-values} < 1 \times 10^{- 5}$ in models before and after heterogeneity adjustments.

We also investigated the underlying biology that may be affected by Cd-associated variations in the placental epigenome. Because we had too few FDR-significant findings to perform an enrichment analysis on only those hits, we tested for GO term and KEGG pathway enrichment among the top 250 CpGs as-sociated with placental Cd after PCT adjustment. The top GO terms included dimethylarginase activity, eye and heart valve development, and heparan sulfate proteoglycan and polysaccharide biosynthetic processing (see Excel Table S5), although none of these enrichments was significant at an FDR threshold of 5%. In contrast, our gene set was enriched with genes from numerous KEGG pathways (see Excel Table S6), 12 of which yielded *p*-values within an FDR threshold of 5% ([Table 4](#t4){ref-type="table"}); these included cell adhesion molecules (CAMs) and tight junctions, multiple cancer pathways, multiple G-protein and nitric oxide signaling pathways, and cytotoxic processes.

###### 

Significantly enriched KEGG pathways (FDR 5%) associated with for genes annotated to the top 250 CpG sites from the PCT-adjusted Meta-analysis.

Table 4 lists KEGG pathway description in the first column; the corresponding n values, DE, and FDR are listed in the other columns.

  KEGG pathway description                    *n*    DE   FDR
  ------------------------------------------- ------ ---- --------
  RAS signaling pathway                       217    6    0.0058
  Tight junction                              163    5    0.0058
  Platelet activation                         122    4    0.019
  Cell adhesion molecules (CAMs)              133    4    0.019
  Taste transduction                          79     3    0.019
  Apelin signaling pathway                    136    4    0.019
  Pancreatic cancer                           61     3    0.026
  Oxytocin signaling pathway                  150    4    0.026
  cGMP-PKG signaling pathway                  157    4    0.026
  Viral carcinogenesis                        191    4    0.030
  Metabolic pathways                          1189   8    0.034
  Natural killer cell mediated cytotoxicity   107    3    0.042

Note: N represents the total genes in the KEGG path, DE represents the number of genes within our top 250 sites. CpG, cytosine-phosphate-guanine methylation site; DE, number of genes within our top 250 sites; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; *n*, total genes in KEGG path.

To explore whether gene expression levels might be associated with variations in DNAM levels at Cd-associated CpGs with meta-analysis $p\text{-values} < 1 \times 10^{- 5}$, we performed an expression quantitative trait methylation (eQTM) ([@c63]) analysis. We regressed the expression levels of any gene within $100\,\text{kb}$ of a candidate CpG site on the DNAM levels of that CpG. Three of these CpGs (cg24000528, cg03917020, and cg23193177) were not within $100\,\text{kb}$ of any genes that yielded detectable RNA from our placental samples. Thus, 14 CpGs and 32 genes were included in this analysis; only *GAS7* was *cis* to multiple CpGs within our set of candidates. We produced 36 linear models ranging between 1 and 7 genes tested per CpG ([Table 5](#t5){ref-type="table"}). Of the 36 eQTM models, 10 yielded FDR-significant linear associations between DNAM and expression of six unique genes (see Figure S5). Of particular note were the associations between our top hit from the meta-analysis and the expression levels of *EXOC3L4* ($\beta_{1} = 1.95$, $p\text{-value} = 0.0043$) and *TNFAIP2* ($\beta_{1} = 1.88$, $p\text{-value} = 0.0055$). Additionally, all five of the Cd-associated *GAS7* CpGs (within or nearby the first exons of variants a, b, and d) were associated with increased *GAS7* expression ([Table 5](#t5){ref-type="table"}). In contrast, DNAM surrounding the first exon of *GAS7* variant c tended to be inversely correlated with mRNA levels ([Figure 3](#f3){ref-type="fig"}).

###### 

Expression quantitative trait methylation (eQTM) results for CpGs with PCT-adjusted meta-analysis $p\text{-values} < 1 \times 10^{- 5}$.

Table 5 lists CpG sites and genes in the first and the second column, respectively. The corresponding beta sub 1, p values, and FDR are listed in the other columns.

  CpG site     Gene           $\beta_{1}$ *p*-Value                FDR
  ------------ ------------ ------------- ------------------------ ------------------------
  cg15345741   *EXOC3L4*             2.28 $5.22 \times 10^{-3}$    0.019
  cg15345741   *TNFAIP2*             2.56 $4.97 \times 10^{-3}$    0.019
  cg11707084   *EHD2*           ${-1}.76$ $4.12 \times 10^{-2}$    0.11
  cg11707084   *GLTSCR2*             0.68 $4.16 \times 10^{-1}$    0.66
  cg11707084   *SEPW1*               0.89 $3.76 \times 10^{-1}$    0.66
  cg16768966   *GAS7*                4.18 $3.15 \times 10^{-6}$    $2.27 \times 10^{-5}$
  cg06100161   *RORA*                4.18 $1.04 \times 10^{-5}$    $6.22 \times 10^{-5}$
  cg19944656   *CYTH1*               0.77 $4.20 \times 10^{-1}$    0.66
  cg19944656   *USP36*               0.99 $3.40 \times 10^{-1}$    0.64
  cg19944656   *TIMP2*          ${-0}.16$ $8.91 \times 10^{-1}$    0.97
  cg19944656   *LGALS3BP*       ${-0}.01$ $9.93 \times 10^{-1}$    0.99
  cg16034168   *RPL22*          ${-0}.21$ $7.18 \times 10^{-1}$    0.97
  cg16034168   *RNF207*              0.94 $1.74 \times 10^{-1}$    0.37
  cg16034168   *ICMT*           ${-0}.52$ $4.18 \times 10^{-1}$    0.66
  cg16034168   *GPR153*         ${-0}.05$ $9.38 \times 10^{-1}$    0.97
  cg16034168   *ACOT7*               2.20 $1.87 \times 10^{-3}$    0.0096
  cg03762242   *GAS7*                4.24 $1.19 \times 10^{-6}$    $1.07 \times 10^{-5}$
  cg11851174   *RAI1*                0.14 $9.08 \times 10^{-1}$    0.97
  cg11851174   *SREBF1*              4.19 $2.21 \times 10^{-3}$    0.0099
  cg11851174   *TOM1L2*              2.35 $1.05 \times 10^{-1}$    0.25
  cg24696183   *KCNQ1*               0.25 $8.03 \times 10^{-1}$    0.97
  cg24696183   *CDKN1C*           $-1.90$ $7.62 \times 10^{-2}$    0.20
  cg24696183   *SLC22A18*         $-1.75$ $1.22 \times 10^{-1}$    0.28
  cg24696183   *PHLDA2*           $-2.74$ $2.00 \times 10^{-2}$    0.065
  cg24696183   *NAP1L4*           $-0.24$ $8.34 \times 10^{-1}$    0.97
  cg02600679   *RNF166*              0.17 $8.49 \times 10^{-1}$    0.97
  cg02600679   *CTU2*                0.42 $5.51 \times 10^{-1}$    0.78
  cg02600679   *PIEZO1*              1.77 $2.27 \times 10^{-2}$    0.068
  cg02600679   *CDT1*             $-0.72$ $4.38 \times 10^{-1}$    0.66
  cg02600679   *APRT*             $-0.06$ $9.41 \times 10^{-1}$    0.97
  cg02600679   *GALNS*               1.17 $1.89 \times 10^{-1}$    0.38
  cg02600679   *TRAPPC2L*            0.15 $8.65 \times 10^{-1}$    0.97
  cg10618704   *GAS7*                3.84 $7.08 \times 10^{-14}$   $1.27 \times 10^{-12}$
  cg10517535   *GAS7*                3.16 $8.86 \times 10^{-10}$   $1.06 \times 10^{-8}$
  cg04267691   *GAS7*                9.17 $8.97 \times 10^{-16}$   $3.23 \times 10^{-14}$
  cg03566291   *SIK1*                0.17 $8.87 \times 10^{-1}$    0.97

Note: Analysis conducted with Rhode Island Child Health Study (RICHS) placental samples for which RNAseq and Illumina Infinium 450K were performed ($n = 200$). CpG, cytosine-phosphate-guanine methylation site; FDR, false discovery rate; PCT, putative constituent cell type.

We then investigated whether the expression levels of the FDR-significant genes from the eQTM analysis were associated with fetal growth metrics standardized by sex and gestational age ([@c20]) ([Table 6](#t6){ref-type="table"}). We found that higher placental expression levels of *TNFAIP2* and acyl-CoA thioesterase 7 (*ACOT7*) were modestly associated with decreasing birth weight *z*-scores, and higher expression of retinoic acid receptor-related orphan receptor alpha (*RORA*) was modestly associated with increased birth weight *z*-scores ($p\text{-values} < 0.05$). Higher expression of *ACOT7* was also associated with decreasing birth length and head circumference *z*-scores ($p\text{-values} < 0.05$). None of the other gene expression levels was associated with birth metrics.

###### 

Associations between expression levels with growth metrics at birth in RICHS ($n = 200$).

Table 6 lists genes in the first column; the corresponding tau values (p-values) for BW, BL, and HC are listed in the other columns.

  Gene        BW                   BL                  HC
  ----------- -------------------- ------------------- --------------------
  *TNFAIP2*   $- 0.099$ (0.039)    $- 0.057$ (0.24)    $- 0.092$ (0.061)
  *EXOC3L4*   $- 0.024$ (0.62)     0.005 (0.91)        $- 0.030$ (0.54)
  *GAS7*      0.012 (0.80)         0.032 (0.51)        0.032 (0.51)
  *RORA*      0.106 (0.026)        0.068 (0.16)        0.077 (0.12)
  *ACOT7*     $- 0.134$ (0.0048)   $- 0.106$ (0.029)   $- 0.145$ (0.0032)
  *SREBF1*    0.032 (0.50)         0.003 (0.95)        $- 0.051$ (0.30)

Note: BW, BL, and HC were sex-specific *z*-scores that have been adjusted for gestational age. Tau represents the Kendall correlation coefficient. BL, birth length; BW, birth weight; HC, head circumference; RICHS, Rhode Island Child Health Study.

Finally, we explored whether top hits from a previous small-sample study ($n = 24$) of placental Cd and DNAM levels ([@c44]) demonstrated associations in our study. In our meta-analysis, one of the top six loci from that study, cg04528060 on chromosome 4 within the ADP-ribosylation factor-like 9 (*ARL9*) gene, demonstrated a nominally significant association with Cd ($\beta_{1} = - 0.49$, $p\text{-value} = 0.014$), with the same direction of effect. However, we did not observe any evidence of sex-specific effects at this or the other 5 CpG sites. We also explored whether any CpGs from our meta-analysis with $p\text{-values} < 1 \times 10^{- 5}$ yielded statistically significant interactions between Cd and fetal sex (see Excel Table S5). Of the 17 models, only cg02600679 within the gene body of piezo type mechanosensitive ion channel component 1 (*PIEZO1*) produced a significant interaction ($p\text{-value} = 0.031$). Stratifying by fetal sex revealed that Cd was associated with increased DNAM at cg02600679 among males ($\beta_{1} = 0.26$, $p\text{-value} = 0.0012$), whereas there was no association among females ($p\text{-value} = 0.97$).

Sensitivity Analyses {#s3.1}
--------------------

We performed sensitivity analyses to *a*) evaluate the linear relationships between $\log_{2}$-Cd and DNAM, and *b*) evaluate the potential confounding effects of maternal smoking during pregnancy. To evaluate the linear relationships, we tested the associations between DNAM and log-Cd at the 17 CpG sites from [Table 3](#t3){ref-type="table"} while adjusting for sex, maternal education, maternal smoking, and PCTs within each cohort; then, we meta-analyzed the results (see Table S1). All 17 models produced nominally significant ($p\text{-values} < 0.05$) linear associations with log-Cd with the same direction of effect, although *p*-values for these associations (ranging between 0.014 and 0.000019) did not produce suggestive significance ($p\text{-values} < 1 \times 10^{- 5}$). To evaluate whether our observed associations between dichotomized Cd and DNAM were driven by the effects of maternal smoking during pregnancy, we reproduced the fully adjusted study-specific models and meta-analyses after excluding all mothers who reported smoking during pregnancy. The associations we observed between Cd and DNAM did vary somewhat after excluding smokers, but there was no strong attenuation of $\beta\text{-coefficients}$ towards the null (see Figures S6 and S7). Among our top hits, the Cd-DNAM associations were only modestly attenuated (see Table S2): $\beta$ coefficients changed by $> 20\%$ for only 3 CpGs and by $> 10\%$ for an additional 5 CpGs; however, only 3 CpGs retained meta-analysis $p\text{-values} < 1 \times 10^{- 5}$. In addition, maternal smoking was not significantly associated with estimated placental heterogeneity in either cohort (see Table S3; minimum T-test $p\text{-value} = 0.09$) or with the expression of our top genes (see Table S4; minimum T-test $p\text{-value} = 0.07$). Our top two hits from the original analysis retained strong associations with Cd when utilizing log-Cd as the independent variable (cg15345741 $\beta_{1} = 0.09$, $p\text{-value} = 5.67 \times 10^{- 4}$; cg11707084 $\beta_{1} = 0.09$, $p\text{-value} = 8.8 \times 10^{- 5}$) and when excluding mothers who reported smoking during pregnancy (cg15345741 $\beta_{1} = 0.20$, $p\text{-value} = 5.6 \times 10^{- 5}$; cg11707084 $\beta_{1} = 0.23$, $p\text{-value} = 8.0 \times 10^{- 8}$).

Discussion {#s4}
==========

We conducted a large EWAS study across two cohorts to examine associations between Cd concentrations and DNAM from human placentae while considering the potential confounding effects of placental tissue heterogeneity and maternal smoking. We further assessed eQTM and associations with birth metrics. We used identical measurement techniques for both DNAM and trace metal measurement in the two cohorts, and the placental concentrations of Cd were similar to the $3.53\,\text{ng}/g$ previously reported in the full NHBCS cohort ([@c49]), and towards the lower end but consistent with other cohorts that have reported concentrations ranging from as low as $1.2\,\text{ng}/g$ to as high as $53.3\,\text{ng}/g$ ([@c17]). We identified Cd-associated variations at two CpGs within a 5% FDR threshold and an additional 15 CpGs with meta-analysis $p\text{-values} < 1 \times 10^{- 5}$. At all but one of these loci, higher Cd was associated with increased DNAM levels, and each of these sites produced linear associations with log-Cd and in the same direction of effect at a nominal significance level ($p\text{-values} < 0.05$) We also found that the DNAM levels at many of these CpGs were associated with the expression patterns of six genes, and the expression of three genes (*TNFAIP2*, *ACOT7*, and *RORA*) was associated with birth metrics.

The observed preference for Cd-associated hypermethylation, as opposed to hypomethylation, is consistent with the findings of previous studies that observed higher Cd to be associated with a higher proportion of hypermethylation at gene promoters from fetal and maternal blood samples ([@c56]) and with increased DNAM at regulatory regions for imprinted genes from cord blood samples ([@c66]). In contrast, others have observed Cd-associated hypomethylation in placental DNA; however, this finding was from a relatively small study that focused on sex-specific associations ([@c44]). Cd has been shown to enhance DNA methyltransferase activity and thus to increase the preponderance of hypermethylated loci, although these effects on DNAM may vary by timing and duration of exposure ([@c60]).

The top hit from our study, cg15345741 is on chromosome 14, approximately $70\,\text{kb}$ and $97\,\text{kb}$ downstream of the *TNFAIP2* and *EXOC3L4* genes, respectively, which encode tumor necrosis factor alpha-induced protein 2 and the exocyst complex component 3 like 4 protein. Higher DNAM at cg15345741 was associated with higher expression of both *TNFAIP2* and *EXOC3L4* and thus may be involved in the regulation of these genes or as a possible marker of their expression, although our findings are not consistent with the promoter methylation paradigm. Other investigators have observed that arsenic-associated DNAM variations in the first exon, particularly within CpG islands, have been associated with increased gene expression in cord blood leukocytes ([@c52]). Furthermore, environmental toxicant--associated DNAM variations in nonpromoter regions have been suggested to represent transcription factor binding activity ([@c39]). Interestingly, the location of our top CpG does overlap with a DNase hypersensitivity region and with multiple putative transcription factor binding sites, which may explain the apparent relationship between DNAM and the expression of *TNFAIP2* and *EXOC3L4*. We also identified the Cd-associated locus cg11707084 on chromosome 19, which is *cis* to six genes, although the expression levels of most of these genes were not detectable in placental tissue, and those that were did not yield associations with DNAM at our candidate loci. Thus, the potential functional role of DNAM at cg11707084 is unclear.

Both *TNFAIP2* and *EXOC3L4* also serve other biological roles that may be important to Cd-associated toxicity. For example, the expression of *TNFAIP2* can be up-regulated by $\text{TNF}\alpha$, retinoic acid, $\text{interleukin-}1\beta$, and other pro-inflammatory and cytotoxic signals ([@c53]; [@c57]). SNPs within *EXOC3L4* have been implicated in affecting $\gamma\text{-glutamyl}$ transferase (GGT) activity ([@c43]), and elevated levels of GGT are recognized markers of oxidative stress ([@c19]), which plays a central role in Cd toxicity. Disrupted epigenetic regulation of these genes and their involvement in placental growth, development, inflammation, and/or oxidative stress responses present compelling potential mechanisms through which Cd may elicit some of its reproductive toxicity.

Our top 250 sites included genes that were significantly enriched for nitric oxide (NO) and G-protein signaling pathways (RAS, apelin, oxytocin, and cGMP-PKG), cancerous processes, cellular adhesion, cellular metabolism, and cytotoxicity. These pathways are consistent with currently recognized mechanisms of Cd-associated toxicity that have primarily been studied in animal or *in vitro* models: altered signal transduction, impaired cellular adhesion, disruptions to the cell cycle, increased oxidative stress, and cytotoxic/apoptotic signaling ([@c64]). We provide evidence that these biologic processes in the human placenta may be perturbed by Cd-associated differential DNAM, despite overall Cd exposures being low and our study samples primarily consisting of healthy pregnancies.

Expression of the *GAS7* gene, which encodes the growth arrest specific 7 protein, was strongly associated with DNAM at all five candidate CpGs that were associated with Cd ($p\text{-values} < 1 \times 10^{- 5}$). Interestingly, the strongest Cd associations were localized near the first exons of transcript variants a, b, and d for *GAS7*, and thus these variations may play roles in Cd-associated alternative splicing of this gene. However, the read-depth of our RNA-seq data was not sufficient to accurately test for variant-specific expression levels; this should be investigated further in future studies given the potential for variant-specific functions that is described below. The *GAS7* gene, which is highly expressed in embryonic cells ([@c45]), mature brain cells, and Purkinje neurons, plays an essential role in neurite outgrowth ([@c76]) and in inducing neuronal cell death ([@c27]); specific functions may be isoform dependent. In the mouse embryo, levels of *GAS7* decrease as the embryo grows, except in neuronal-specific epidermal cells, in which expression remains high ([@c45]). *GAS7* expression also plays an essential role in other nonneuronal growth functions, such as osteoblast differentiation and bone development ([@c10]). Furthermore, neural outgrowth and arborization are shared functions between the exocyst and *GAS7* ([@c38]; [@c76]), whereas *TNFAIP2* expression has been associated with some neurodegenerative conditions ([@c9]; [@c12]). Relatively few studies have investigated relationships between perinatal Cd exposure and neurodevelopment, although some studies suggest an association with impaired cognition ([@c34]; [@c55]), which raises some questions about the possible roles of the above-mentioned genes in Cd-associated cognitive and neurobehavioral deficits. However, the functional roles of these genes in human placental tissue are not well understood. Thus, it is unclear how, or whether, Cd-associated differential placental DNAM and expression may affect early-life cognitive function; this should be the focus of additional research.

Genes known to contribute to neurite outgrowth are sometimes also involved in regulating placental angiogenesis, as has been shown for vascular endothelial growth factor (VEGF) and neurotrophins ([@c54]). Interestingly, sterol regulatory element binding proteins (SREBPs) such as *SREBF1*, whose expression was strongly correlated with one of our top hits, play key roles in VEGF-induced angiogenesis ([@c77]). Additionally, inappropriate placental vascularization can result in fetal growth restriction or other pregnancy complications ([@c54]). In our study, the expression of *GAS7*, *EXOC3L4*, and *SREBF1* was not associated with standardized percentiles for birth weight, head circumference, or birth length and thus may not be directly related to fetal growth. In contrast, expression of *TNFAIP2*, *ACOT7*, and *RORA* was associated with fetal growth. *ACOT7*, which encodes acyl-CoA thioesterase 7, is involved in lipid metabolism in neuronal cells and may prevent neurotoxicity ([@c15]); it also promotes pro-inflammatory activities by up-regulating arachidonic acid production ([@c8]). *RORA*, which encodes the retinoic acid receptor-related orphan receptor alpha, is involved in numerous developmental processes including innate immune system development, regulation of inflammatory responses, and neuronal survival and growth, as well as in lipid and glucose metabolism ([@c13]). One common biological thread that differentiates *TNFAIP2*, *ACOT7*, and *RORA* from *GAS7*, *EXOC3L4*, and *SREBF1* is their role in mediating inflammatory and immune responses. Thus, although we observed numerous Cd-associated variations in DNAM among genes involved in neurodevelopment and cellular growth processes, variations involved in inflammatory and immune signaling disruption may affect fetal growth. Additionally, these genes are involved in glucose and insulin signaling, which is consistent with the endocrine-disruptive effects of cadmium, and may have implications for metabolic health. *GAS7* influences adiposity, fat metabolism, and insulin signaling ([@c75]). *SREBF1* mediates insulin action, and polymorphisms and DNA methylation variations within *SREBF1* increase predisposition to type II diabetes ([@c22]; [@c46]). *ACOT7* is a key regulator of glucose response and is more highly expressed in pancreatic $\beta\,\text{cells}$ of those with type II diabetes ([@c41]). *RORA* is involved in lipid metabolism and insulin sensitivity, and it is associated with obesity and type II diabetes ([@c29]).

Other epidemiologic studies of maternal Cd and birth/pregnancy outcomes have found that higher Cd may affect essential metals transport ([@c33]); reduce expression of a protocadherin involved in neuronal development ([@c18]); and affect the DNAM of genes involved in cell death, lipid metabolism, and cancer pathways ([@c56]). Similarly, electronic waste (e-waste) exposure, which is associated with higher placental concentrations of toxic metals including Cd, may influence differential expression of proteins involved in immune and metabolic processes ([@c74]). The top hits from a small-sample EWAS of placental Cd and DNAM indicated differential methylation of genes involved in cellular metabolism, growth, and cell damage response ([@c44]). We were able to reproduce Cd-associated DNAM variations for one top hit from that study, cg04528060 in the 5′ untranslated region (UTR) of the *ARL9* gene (meta-analysis $p\text{-value} < 0.05$), with the same direction of effect. Notably, the *ARL9* gene encodes a GTP-binding protein that is similar to members of the RAS superfamily ([@c37]), and RAS signaling was the most highly enriched KEGG pathway from our study.

Several studies have investigated relationships between maternal Cd biomarkers and DNAM in cord blood. One study found that maternal blood Cd was associated with higher cord blood DNAM at the paternally expressed gene 3 (*PEG3*) differentially methylated region (DMR) and observed indiciations of sex-specific effects and possible antagonism of effects by Zn ([@c66]). In our study, the four CpGs within the *PEG3* DMR (Chr. 19: 57,351,945--57,352,096; UCSC Genome Browser, GRCH37/hg19) ([@c47]) produced $p\text{-values} > 0.05$. A genome-wide study found that genes involved in regulating expression, cell cycle, cell death, and nervous system development were differentially methylated by Cd exposure ([@c56]); many of the same processes were identified in our enrichment analysis. Another genome-wide study observed higher DNAM at nine of their top loci associated with maternal Cd, consistent with our observation of hypermethylation among top hits ([@c32]). The CpG with the second-strongest effect in that study, cg16667631, showed a strong effect in the same direction of effect in our meta-analysis.

The preponderance of similar biological processes associated with Cd across multiple studies with different technologies, populations, and tissues, is striking and suggests that common mechanisms may be affected by Cd exposure during pregnancy. The findings from our study should be interpreted within the context of this study's limitations. This was an observational study in which placental Cd concentrations and DNAM levels were both measured in placenta at term. Thus, temporality between the Cd concentrations and variations in DNAM could not be established, and the observed associations at term may not be representative of Cd and DNAM associations throughout development. Although we did estimate and adjust for cellular heterogeneity, we used a reference-free approach that was data-driven rather than biology-driven. Future studies of placental DNAM would benefit greatly from the production of an appropriate cell-type-specific methylome for placental tissues. Although we adjusted for likely confounders in our study, we also cannot rule out the possibility that unmeasured or residual confounding may have affected our observations; one of the most likely confounders of these associations was maternal smoking, which is a common source of high Cd exposure. However, we adjusted for maternal smoking in our primary analysis and further evaluated potential bias with a sensitivity analysis in which we excluded mothers who reported smoking during pregnancy. These analyses indicated that the observed associations between Cd and DNAM were largely independent of maternal smoking during pregnancy. We utilized a 5% FDR cutoff to identify our top statistically significant loci; however, given the small number of significant hits, we performed follow-up DNAM expression analyses on all loci with raw $p\text{-values} < 1 \times 10^{- 5}$. Thus, there are likely some false positive findings among these hits. Power is a common problem in epigenetic epidemiology given the high dimensionality of the data and the small effect sizes ([@c6]); therefore, we recommend further replication in other independent study samples. Further, both samples utilized in this study were from the New England region of the United States and consisted predominantly of healthy white mothers. Thus, the generalizability of our findings to populations in different regions of the world and to those with different racial and ethnic backgrounds may be limited. However, to our knowledge, this was the largest study yet to examine the relationships between placental Cd and DNAM and the first to account for and evaluate associations with estimated cellular heterogeneity.

The loci that we did identify are involved in biological processes known to be affected by Cd toxicity and thus are strong candidates for future studies. We observed these associations in two healthy populations with relatively low exposure levels. In the United States, exposure to Cd has declined since the late 1980s, which is primarily attributed to declining smoking rates ([@c61]). However, Cd is still detectable in numerous commonly consumed foods ([@c5]), and exposure prevalence remains quite high ([@c58]). Additionally, e-waste recycling and disposal are emerging sources of environmental Cd (and other toxic metals) contamination, particularly in developing countries ([@c59]). These sources of exposure raise some concerns about the potential threshold for Cd-associated reproductive toxicity and whether current dietary intake guidelines and efforts to reduce tobacco smoke exposure during pregnancy adequately protect against adverse birth and pregnancy outcomes. We encourage further molecular epidemiologic studies of the associations between Cd and DNAM in placental tissue, particularly in populations with higher exposure levels and different ethnic backgrounds; we also encourage studies of the associations between dietary intake-- and smoking-related Cd exposure with the placental accumulation of Cd. Understanding these relationships can help us determine whether changes to current guidelines and recommendations could reduce Cd-associated adverse reproductive outcomes. Finally, the genes whose expression levels were associated with DNAM at our top hits are multifunctional and are involved in neurodevelopmental and/or neurodegenerative processes, cellular growth processes, and inflammatory/immune signaling. We also found that the expression levels of three of these genes were associated with infant birth weight. Thus, additional future studies should investigate whether differential placental epigenetic regulation and expression of *GAS7*, *EXOC3L4*, *SREBF1*, *RORA*, *ACOT7*, and *TNFAIP2* are associated with cognitive/neurobehavioral, growth, and immune outcomes in children.

Conclusion {#s5}
==========

Cadmium is a toxic environmental pollutant that can impair fetal development, although mechanisms underlying this developmental toxicity are unclear. Because cadmium can accumulate in the placenta during pregnancy, we hypothesized that some of this toxicity may be due to disrupted placental functions. We showed that placental cadmium was associated with differential placental DNAM at multiple loci that are involved in cellular growth processes, metabolism, and inflammatory signaling. We also observed corresponding DNAM-expression associations at many of the genes in close genomic proximity to these loci. The expression of the genes involved in inflammatory and immune signaling (*RORA*, *ACOT7* and *TNFAIP2*) was also associated with birth size. The present study provides supporting evidence that disrupted placental epigenetic regulation of cellular growth and immune/inflammatory signaling could play a role in Cd-associated reproductive toxicity in human pregnancies.
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